Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Ingresos
20
20
18
26
23
21
Crecimiento de los Ingresos (YoY)
5%
11%
-31%
13%
10%
-32%
Costo de los ingresos
17
17
15
13
14
14
Utilidad bruta
3
2
3
13
8
7
Venta, General y Administración
14
12
11
10
9
8
Investigación y Desarrollo
12
8
7
9
9
7
Gastos de Operación
27
22
19
20
19
16
Otras Ingresos (Gastos) No Operativos
--
-12
0
-9
-1
-1
Ingreso antes de impuestos
-20
-30
-6
-19
-13
-9
Gasto por Impuesto a la Renta
0
0
0
0
0
--
Ingreso Neto
-20
-30
-6
-19
-13
-9
Crecimiento de la Utilidad Neta
-26%
400%
-68%
46%
44%
-325%
Acciones en Circulación (Diluidas)
11.02
9.95
9.01
4.99
3.89
3.89
Cambio de Acciones (YoY)
0%
11%
81%
28%
0%
0%
EPS (Diluido)
-1.86
-3.03
-0.74
-3.93
-3.48
-2.36
Crecimiento de EPS
-26%
307%
-81%
13%
47%
-286%
Flujo de efectivo libre
-18
-19
-16
-12
-9
-7
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
15%
10%
16.66%
50%
34.78%
33.33%
Margen de operación
-114.99%
-95%
-83.33%
-26.92%
-47.82%
-38.09%
Margen de beneficio
-100%
-150%
-33.33%
-73.07%
-56.52%
-42.85%
Margen de flujo de caja libre
-90%
-95%
-88.88%
-46.15%
-39.13%
-33.33%
EBITDA
-22
-19
-15
-7
-11
-8
Margen de EBITDA
-110%
-95%
-83.33%
-26.92%
-47.82%
-38.09%
D&A para EBITDA
1
0
0
0
0
0
EBIT
-23
-19
-15
-7
-11
-8
Margen de EBIT
-114.99%
-95%
-83.33%
-26.92%
-47.82%
-38.09%
Tasa de Impuesto Efectiva
0%
0%
0%
0%
0%
--
Estadísticas clave
Cierre Anterior
$17.13
Precio de apertura
$17.43
Rango del día
$17.13 - $17.64
Rango de 52 semanas
$14.14 - $22.5
Volumen
44.8K
Volumen promedio
98.0K
EPS (TTM)
-1.90
Rendimiento de dividendos
--
Cap. de mercado
$221.4M
¿Qué es MDWD?
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.